On March 24, 2024, the Center for Drug Evaluation of China’s National Medical Products Administration announced that the innovative drug Teclistamab is proposed to be designated as a breakthrough therapy for the monotherapy treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
As a pioneer in international oncology care, the International Department of Beijing South Region Oncology Hospital stands at the forefront of medical innovation. We have now opened a dedicated consultation channel for global patients, offering professional cancer treatment assessments and personalized care plans through our international medical team.
Why Choose the International Department of Beijing South Region Oncology Hospital?
- Expert Medical Team: Comprising leading hematology and oncology specialists from both China and abroad, with extensive experience in targeted therapy and immunotherapy.
- International Standards of Care: Strict adherence to global multiple myeloma treatment guidelines, providing comprehensive management from diagnosis through recovery.
- Seamless Communication Support: Multilingual medical coordinators assist throughout your journey, addressing all cross-border needs including language, visa, and accommodation.
- Access to Cutting-Edge Therapies: Leveraging national breakthrough therapy policies to help eligible patients gain faster access to innovative treatments.
Act Now to Secure Your Treatment Advantage
If you or a loved one is facing challenges in multiple myeloma treatment, contact us today—
��� Global Hotline: 400-880-3716 (24-hour multilingual support)
��� WeChat: 17801183037 (Please add with note “Myeloma Consultation”)
��� Official Emails:
100085_010@163.com
myimmnet@163.com
A New Era of Treatment Has Arrived—Hope Is Within Reach
Teclistamab, the world’s first approved BCMA×CD3 bispecific antibody, precisely eliminates myeloma cells by activating the patient’s own immune system. Clinical trial data have demonstrated significant efficacy in patients with relapsed or refractory disease.
No matter where you are in the world, the International Department of Beijing South Region Oncology Hospital is committed to being your strongest partner in the fight against cancer—offering top-tier medical expertise, compassionate care, and efficient communication.
Call 400-880-3716 or email myimmnet@163.com today, and let us help bring new hope to your journey.
Post time: Mar-26-2026